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Abstract
 
The cysteine proteases known as caspases play a central role in most apoptotic pathways. Here,
we show that caspase inhibitors arrest the maturation of human erythroid progenitors at early
stages of differentiation, before nucleus and chromatin condensation. Effector caspases such as
caspase-3 are transiently activated through the mitochondrial pathway during erythroblast dif-
ferentiation and cleave proteins involved in nucleus integrity (lamin B) and chromatin con-
densation (acinus) without inducing cell death and cleavage of GATA-1. These observations
indicate a new function for caspases as key proteases in the process of erythroid differentiation.
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Introduction
 
The production of red blood cells follows the sequential
formation, from erythroid progenitors, of proerythro-
blasts—basophilic, polychromatophilic, and orthochro-
matic erythroblasts. Then, orthochromatic erythroblasts un-
dergo terminal maturation leading to enucleation (1). The
glycoprotein hormone erythropoietin (Epo) positively reg-
ulates erythropoiesis by preventing apoptosis and stimulat-
ing differentiation and proliferation of erythroid progenitors
and erythroblasts (2). Epo protects cells from apoptosis by
upregulating the expression of the antiapoptotic protein
Bcl-xL (3, 4). Conversely, Epo deprivation results in caspase
activation and apoptosis (5). The transcription factor
GATA-1 is required for Epo-mediated upregulation of Bcl-
xL (6) and expression of erythroid genes involved in ery-
throid differentiation (7). In the absence of GATA-1, the
differentiation process is arrested at the basophilic erythro-
blast stage, and cells die by apoptosis. A negative feedback
loop was recently described in which the ligand of Fas
(APO-1/CD95) expressed by mature erythroblasts activated
Fas-mediated cell death of immature erythroblasts (8). Fas
ligation results in the activation of caspase-8, then caspase-3,
and the cleavage of GATA-1, the inactivation of which leads
to maturation arrest at the basophilic erythroblast stage of
differentiation (9). Altogether, these observations argued for
a role of caspases in the negative regulation of erythropoiesis.
The morphology of erythroblasts changes dramatically
during terminal erythroid differentiation. Little is known
about the molecular mechanisms of these changes, which
include nuclear and chromatin condensation, loss of or-
ganelles, and enucleation (10). Some of these morphologi-
cal changes share similarities with features occurring during
apoptosis as a consequence of caspase activation (11).
Therefore, in this report we have investigated whether
caspases could play a role during erythroid differentiation.
 
Materials and Methods
 
In Vitro Generation of Erythroid Cells.
 
Erythroid cells were
generated from CD34
 
1
 
 progenitor cells in serum-free medium in
the presence of Epo (2 mU/ml) 
 
1
 
 IL-3 (10 ng/ml) 
 
1
 
 stem cell
factor (SCF; 50 ng/ml) (Epo) without or with TGF-
 
b
 
1 (2 ng/
ml) (Epo 
 
1 
 
TGF-
 
b
 
1) as previously described (12).
 
Cell Proliferation, Differentiation, and Apoptosis Assays.
 
Through-
out, the culture cell differentiation was assessed by morphological
analysis of cells after cytocentrifugation and May-Grünwald-
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Giemsa coloration, and by analysis of glycophorin A and he-
moglobin expression by flow cytometry and benzidine staining,
respectively, as previously described (12). Cell proliferation was
assessed by counting cells every day after trypan blue dye ex-
clusion staining (12). Apoptosis was assessed by annexin V
binding and propidium iodide (PI) staining as previously de-
scribed (12).
 
Caspase Assays.
 
Caspase activities were evaluated by DEVD-
AFC, IETD-AFC, LEHD-AFC, VDVAD-AFC, and ZEID-
AFC cleavage in fluorogenic assay (Calbiochem) as previously
described (13).
 
Mitochondrial Transmembrane Potential Study.
 
The cationic li-
pophilic fluorochrome 3,3
 
9
 
-dihexyloxacarbocyanine (DiOC6[3];
Sigma-Aldrich) was used to measure the transmembrane potential
(
 
DC
 
) as described (14). 
 
DY
 
 disruption was assessed by cytometer
analysis after cell labeling with DiOC6(3) and PI. The variation
in 
 
DY 
 
was also investigated by microscopic fluorescence and cy-
tometric analysis after cell labeling with the fluorescent carbocya-
nine dye 5,5
 
9
 
,6,6
 
9
 
-tetrachloro-1,1
 
9
 
,3,3
 
9
 
-tetraethylbenzimidazol-
carbocyanine iodide (JC-1; Alexis). To assess nuclear integrity,
5 
 
3 
 
10
 
5
 
 cells/ml were first incubated in the presence of Hoescht
33342 (Sigma-Aldrich) for 30 min (this first step was not per-
formed for cytometric analysis) before being incubated with 10
 
m
 
g/ml JC-1 for 30 min at 37
 
8
 
C in a humidified atmosphere of
5% CO
 
2
 
. Cells were then washed once with 1
 
3
 
 PBS and resus-
pended in 250 
 
m
 
l of 1
 
3 
 
PBS. Highly negative membrane poten-
tial in mitochondria produce JC-1 orange-red fluorescence. Loss
of mitochondrial transmembrane potential results in green fluo-
rescence and loss of the red fluorescence.
 
Reagents and Antibodies.
 
z-VAD-fmk and DEVD-cmk
(Bachem) were resuspended in methanol and added at the indi-
cated concentration. Anti-CD95 antibody (clone CH-11; Eu-
romedex-Upstate Biotechnology) was added in the culture sys-
tem at the time and concentration indicated (see Fig. 2 E).
For detection of caspase-3 (BD PharMingen), poly(ADP-
ribose) polymerase (PARP; Boehringer Mannheim), ICAD (in-
hibitor of caspase-activated DNase [CAD]) (DFF45; Euromedex-
Upstate Biotechnology), lamin B (provided by J. Courvalin,
Centre National de la Recherche Scientifique, Paris, France), aci-
nus (provided by Y. Tsujimoto, Osaka University Medical
School, Suita, Japan), HSP 90 (StressGen), and GATA-1 (pro-
vided by I. Dussanter, INSERM U363, Hopital Cochin, Paris,
France), cells were lysed in Laemmli buffer or in 1% SDS, 10 mM
Tris, pH 7.4, 1 mM vanadate, 1 mM PMSF, 1 mM dithiothrei-
tol, and 10 
 
m
 
g/ml leupeptin, aprotinin, and pepstatin. Protein
concentration was measured in the supernatant by the use of mi-
cro BCA protein assay (Pierce Chemical Co.). Proteins were ana-
lyzed by standard immunoblot procedure as described earlier (13).
 
Results and Discussion
 
To determine whether caspases could play a role in ter-
minal erythroid differentiation, we used a two-step amplifi-
cation culture system in which normal human CD34
 
1
 
 pro-
genitor cells were amplified during 7 d in the presence of
SCF, IL-3, and IL-6. Then, CD36
 
1
 
 erythroid progenitors
were isolated and cultured in the presence of SCF, IL-3,
Figure 1. The caspase inhibitor z-VAD-fmk arrests erythroid matura-
tion at the basophilic stage. CD36 cells (2 3 105 cells/ml) were cultured
for 8 d in the presence of Epo or Epo 1 TGF-b1 with (1) or without
(2) 150 mM z-VAD-fmk (ZVAD). Every 2 or 3 d, cells were diluted to
2 3 105 cells/ml, and cytokines and z-VAD-fmk were added. (A) Cell
morphology was examined after May-Grünwald-Giemsa staining on day
8 of the culture. Absolute numbers of each type of erythroblasts (imma-
ture cells, mature cells, and erythrocytes) in the presence or absence of
z-VAD-fmk are indicated above percentages. (B) Percentage of cells con-
taining hemoglobin was estimated after benzidine staining. All results are
the mean of four independent experiments. 
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and Epo. After 7 d of this second step of culture (day 7), all
stages of erythroblast differentiation were observed (Fig. 1
A), though the percentage of enucleated erythrocytes re-
mained limited to 1–5%. To increase the percentage of ma-
ture erythroblasts and erythrocytes, TGF-
 
b
 
1 (2.5 ng/ml)
was added to the culture medium of CD36
 
1
 
 cells. While
inhibiting cell proliferation, TGF-
 
b
 
1 accelerates and syn-
chronizes erythroid differentiation with production at day 7
of 75 and 25% of mature polychromatic or orthochromatic
erythroblasts and enucleated red cells, respectively (12).
Addition to culture medium from 50–200 
 
m
 
M z-VAD-
fmk, a permeant broad spectrum inhibitor of caspases (15),
at the beginning (day 0) of CD36
 
1
 
 cell culture, induced a
dose-dependent decrease of terminal erythroid differentia-
tion. At 150 
 
m
 
M, z-VAD-fmk completely inhibited ery-
throid differentiation at the basophilic erythroblast stage, be-
fore nucleus and chromatin condensation (Fig. 1 A). This
inhibitory effect was observed both in the absence and in
the presence of TGF-
 
b
 
1 (Fig. 1 A). These observations
suggested that caspase activation was required for erythro-
blast maturation after the basophilic stage of differentiation.
To further explore this hypothesis, we added z-VAD-fmk
to CD36
 
1
 
 cell culture medium at various times after cul-
ture initiation. When z-VAD-fmk was added at day 5 of
culture in the absence of TGF-
 
b
 
1, terminal erythroid dif-
ferentiation although reduced was not totally inhibited.
Similarly, addition of z-VAD-fmk after 3 d of culture in
the presence of TGF-
 
b
 
1, a time when most of the cells
Figure 2. Caspase-3, -2, and -9 are transiently activated, and PARP is cleaved during erythroid differentiation. DEVD-AFC peptide cleavage activity
(caspase-3/-7) was monitored in whole cell lysates from 0.5 3 106 CD361 cells cultured for indicated times (day 2, 3, 5, 7; d2, 3, 5, 7) in the presence of
Epo or Epo 1 TGF-b1. Addition of 150 mM z-VAD-fmk (ZVAD) in all conditions inhibited caspases activation. Results are expressed as mean percent-
age 6 SD (n 5 3) of the activity measured in cells deprived for 12 h of growth factors (Deprived). (B and C) Immunoblots were performed on whole cell
lysates from 0.5 3 106 CD361 cells either deprived of growth factors for 12 h (Deprived) or cultured for indicated times in the presence of Epo to detect
the 32-kD procaspase-3 and its p20, p19, and p17 cleavage products (B) or the native 116-kD PARP (PARP-p116) and its 85-kD cleavage product
(PARP-p85) (C). Arrowheads indicate localization of specific products. HSP90 is shown as a loading control. (D) CD36 cells (2 3 105 cells/ml) were
cultured in the presence of Epo with (1) or without (2) 150 mM DEVD-cmk (DEVD). Every 2 or 3 d, cells were diluted to 2 3 105 cells/ml, and cy-
tokines and DEVD-cmk were added. Cell morphology was examined after May-Grünwald-Giemsa staining on day 8 of the culture. (E) The hydrolysis
of IETD-AFC (caspase-8), LEHD-AFC (caspase-9), and VDVAD-AFC (caspase-2) peptide substrates was monitored in whole cell lysates from 0.5 3 106
CD361 cells cultured for indicated times in the presence of Epo or Epo 1 TGF-b1. For caspase-3, -9, and -2 activation; results are expressed as percent-
age of the activity measured in 12-h growth factor–deprived cells (Deprived), and results for caspase-8 activity (A) are expressed as percentage of the ac-
tivity measured in lysates of cells cultured with Epo 1 500 ng/mL of an agonist anti-CD95 (Fas) mAb (Fas-L) for 12 h. 
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were at the end of basophilic stage of differentiation or
already mature (polychromatophilic or orthochromatic
erythroblasts), erythroid differentiation was no longer
inhibited and enucleation occurred normally (data not
shown). Addition of z-VAD-fmk to the culture medium of
CD36
 
1
 
 cells also slightly reduced the number of hemoglo-
binized cells and their hemoglobin content, as determined
by benzidine staining, in correlation with the blockade of
maturation (Fig. 1 B). HPLC analysis of hemoglobin syn-
thesis did not show any influence of z-VAD-fmk on the
pattern of synthesized hemoglobin chains (not shown). Al-
together, these results suggested that caspase activation
might be required for earlier phases of erythroblast differ-
entiation, while later events such as enucleation could be
caspase independent.
Based on their structure and their ordering in cell death
pathways, caspases have been classified into initiator and ef-
fector enzymes (16). Schematically, effector caspases, which
include caspase-3, -6, and -7, cleave a variety of cellular
substrates, while initiator caspases such as caspase-2, -8, and
-9 control the activation of the former enzymes. To inves-
tigate which caspases were activated during normal ery-
throid differentiation, we studied the ability of cytosolic ex-
tracts from erythroid cells at various stages of differentiation
to cleave fluorogenic peptide substrates (13). Cytosolic ex-
tracts of cells cultured in the presence of Epo cleaved the
peptide substrate DEVD-AFC, suggesting activation of
caspase-3 and/or caspase-7. This cleavage activity increased
during the first 5 d of culture, reaching 75% of the activity
measured in Epo-starved cells, then decreased the last 2 d
of culture (Fig. 2 A). When the cells were cultured in the
presence of Epo 
 
1 
 
TGF-
 
b
 
1, this DEVDase activity, al-
though following the same kinetic profile with the same
magnitude, occurred earlier, with a maximum at day 2. As
expected, these activities were totally inhibited by addition
of z-VAD-fmk (Fig. 2 A). Therefore, the kinetics of DEV-
Dase activity were in accordance with the lack of effect of
z-VAD-fmk on the later stages of erythroid maturation.
To determine whether DEVDase activity measured in
cells undergoing erythroid maturation was related to
caspase-3 activation, we performed immunoblot analyses.
Procaspase-3 was observed to be cleaved to the active en-
zyme (p17 fragment; Fig. 2 B; reference 17). Notably,
while this band was clearly individualized in the positive
control from Epo-deprived erythroblasts, intermediate p20
and p19 bands were observed in erythroblasts cultured in
the presence of Epo, suggesting that procaspase-3 proteoly-
sis was less efficient during normal erythroid maturation
Figure 3. Mitochondrial trans-
membrane potential (DY) is dis-
rupted during erythroid differen-
tiation. For indicated times, DY
disruption was assessed (A) by
cytometer analysis after cell la-
beling with DiOC6(3) and PI.
Cells with disruption of DY
were DiOC6(3) negative and PI
negative. A positive control of
apoptosis was obtained by cyto-
kines deprivation of CD361 cells
for 12 h (Deprived) (B) by fluo-
rescence microscopy and cyto-
metric analysis of cells labeled
with the JC-1 fluorescent dye.
Hoescht 33342 staining showed
nucleus morphology. 
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than during starvation-induced apoptosis. Cleavage of the
116-kD PARP nuclear enzyme into a 85-kD fragment
during erythroblast maturation further confirmed the acti-
vation of one or several effector caspases during the differ-
entiation process (13, 18) (Fig. 2 C). To emphasize the role
of caspase-3, we cultured cells with 150 
 
m
 
M of DEVD-
cmk, an inhibitor that is more specific for caspase-3 and re-
lated caspases than z-VAD-fmk. As expected, DEVD-cmk
inhibited maturation with the same magnitude as z-VAD-
fmk (Fig. 2 D).
Two main pathways leading to caspase activation have
been described (19). One involves death receptors such as
Fas and results in the activation of the initiator caspase-8
that, in turn, activates effector caspases. This pathway is
used for the negative regulation of erythropoiesis by Fas
ligand (Fas-L) and leads to GATA-1 cleavage (9). The
other pathway involves the disruption of the 
 
DY
 
, resulting
in opening of the permeability transition pore and the mi-
tochondrial release of several procaspases, including pro-
caspase-9 and -2 (20) as well as apoptogenic factors (21).
These phenomena result in activation of the caspase cas-
cade through the initiator enzyme caspase-9. To determine
whether one of these pathways was involved in caspase ac-
tivation during normal erythropoiesis, we studied the abil-
ity of cell extracts to cleave
 
 
 
in vitro the fluorogenic pep-
tides IETD-AFC, VDVAD-AFC, and LEHD-AFC that
mimic caspase-8, -2, and -9 targets, respectively. While a
time-dependent cleavage of LEHD-AFC and VDVAD-
AFC was clearly identified (Fig. 2 E), suggesting caspase-9
and -2 activation, no cleavage of IETD-AFC was detected,
suggesting that neither caspase-8 nor a related caspase was
involved in normal erythroid differentiation (Fig. 2 E). In-
volvement of the mitochondria in the pathway leading to
caspase activation during erythroid differentiation was fur-
ther confirmed by using the potential sensitive dyes
DiOC6(3) and JC-1 that allow study of the mitochondrial
transmembrane potential 
 
DY
 
 (14). While the cells cultured
for 2 d in the presence of Epo incorporated DiOC6(3), as
expected from viable cells, this incorporation decreased sig-
nificantly at day 4, demonstrating a disruption of the 
 
DY
 
during normal erythroid differentiation (Fig. 3 A). Simi-
larly, at day 4, the JC-1 ratio orange-red over green fluo-
rescence was significantly reduced (Fig. 3 B), further
demonstrating that 
 
DY
 
 was disrupted during erythroid
maturation. Nucleus counterstaining by Hoescht showed
clearly that mitochondrial depolarization occurred in non
apoptotic cells (Fig. 3 B).
Reduction of the mitochondrial transmembrane poten-
tial and activation of the caspase cascade usually leads to ex-
ternalization of phosphatidyl serine on the plasma mem-
brane, DNA degradation, and apoptotic cell death (21). In
our system of culture and in accordance with previous ob-
servations (22), 
 
,
 
5–10% of erythroid cells exhibited fea-
tures of apoptosis as assessed by annexin V binding/PI
staining (Fig. 4 A), and internucleosomal DNA fragmenta-
tion could not be detected (data not shown). These two
findings excluded the possibility that activation of caspases
may favor erythroid maturation by inducing apoptosis in a
Figure 4. Caspase activation does not induce either phosphatidylserine ex-
ternalization or GATA-1 cleavage. (A) Cells cultured for 5 d in the presence of
Epo or Epo 1 TGF-b1 with (1ZVAD) or without (2ZVAD) 150 mM
z-VAD-fmk were labeled with annexin V and PI as described earlier. As nega-
tive and positive controls, cells were deprived of cytokines for 12 h (Deprived)
with or without z-VAD-fmk, respectively. (B) Expression of the 46-kD ery-
throid transcription factor GATA-1 was studied by immunoblot in whole cell
lysates from 0.5 3 106 CD361 cells deprived of growth factor for 12 h (De-
prived) or cultured for indicated times with Epo. 
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subset of erythroid cells and strongly suggested that inhibi-
tion of red cell formation by z-VAD-fmk was not due to a
selection of immature nonapoptotic cells. In addition, the
disappearance of the transcriptional factor GATA-1 ob-
served by immunoblotting in Epo-deprived erythroid cells
undergoing caspase-dependent apoptosis was not identified
during the normal maturation of erythroblasts (Fig. 4 B).
Other potential targets for caspases during erythroblastic
maturation include critical proteins for nucleus integrity.
Lamin B, which is highly expressed in differentiating eryth-
roblasts (23, 24), forms a fibrous meshwork on the nucleo-
plasmic surface of the nuclear membrane. In cells undergo-
ing apoptosis, lamin B was shown to be cleaved by caspase-6
(25), an effector caspase that is activated by caspase-3 in
the proteolytic cascade (26). By using a peptide substrate
(ZEID-AFC) that mimics the caspase-6 target site, we ob-
served that caspase-6 is activated during erythroid matura-
tion (Fig. 5 A). Accordingly, immunoblot analyzes showed
that lamin B was cleaved during the differentiation process
(Fig. 5 A). Inhibition of caspase activation by z-VAD-fmk,
which blocked nuclear condensation, also inhibited lamin
B cleavage, further supporting a correlation between
caspase activation and morphological changes observed
during erythroid maturation. Recently, the nuclear protein
acinus was shown to play a role in chromatin condensation
associated with apoptosis when cleaved by caspase-3 (27).
This protein is devoid of endonuclease activity and so dif-
fers from DFF40/CAD that possesses both activities (chro-
matin condensation and endonuclease activities) (28).
DFF40 interacts and is specifically inhibited by DFF45/
ICAD. During apoptosis, caspase-3 cleaves DFF45, thereby
releasing DFF40 that digests DNA. Both acinus and
DFF45/ICAD were expressed in our cultured cells and
were cleaved in Epo-deprived cells undergoing apoptosis
(Fig. 5 B). By immunoblotting, we observed that the ex-
pression of DFF45/ICAD remained unchanged during
normal erythroid differentiation, while the native 96-kD
acinus protein had almost disappeared at day 7 of CD361
cell culture in the presence of Epo. The disappearance of
the native acinus was related to the appearance of its active
23-kD fragment and that was prevented by z-VAD-fmk
(Fig. 5 B). In contrast, no cleavage of DFF45 could be de-
tected during erythroid differentiation (Fig. 5 B).
Taken together, our data demonstrate that normal ery-
throid differentiation requires the transient activation of sev-
eral caspases. These enzymes have been involved in several
physiological processes, including cell death, inflammation,
and T cell proliferation (29). In erythroid cells, we show
here that caspases are activated before the process of enu-
cleation and cleave several proteins otherwise implicated in
the apoptotic process such as acinus and lamin B. Cleavage
of these proteins may account for the nuclear structural
changes associated with the maturation of erythroblasts.
These changes could also influence gene expression during
Figure 5. Cleavage of acinus
and lamin B but not DFF45/
ICAD during erythroid differenti-
ation. (A) Top: hydrolysis of
ZEID-AFC was monitored in
whole cell lysates from 0.5 3 106
CD361 cells cultured for indicated
times in the presence of Epo or
Epo 1 TGF-b1. Results are ex-
pressed as mean percentage 6 SD
(n 5 3) of the activity measured in
cells deprived for 12 h of growth
factors (Deprived). Addition of
z-VAD-fmk 150 mM (ZVAD) in-
hibited caspase-6 activation in all
conditions of culture. Bottom: im-
munoblot analysis of the 70-kD
lamin B and its 45-kD cleavage
product in whole cell lysates from
0.5 3 106 CD361 cells deprived of
growth factor for 12 h (Deprived),
cultured for indicated times with
Epo, or cultured for 5 d with
Epo  1  150  mM z-VAD-fmk
(1ZVAD). (B) Immunoblot anal-
ysis of the 98-kD protein acinus,
its 23-kD cleavage product, and
the 48-kD DFF45/ICAD protein
in whole cell lysates from CD361
cells cultured for indicated times
with Epo or Epo 1 150 mM
z-VAD-fmk for 5 d (1ZVAD), or
with Epo 1 TGF-b1 for 2 d. As
positive control of apoptosis, cells
were deprived with growth factors
for 12 h (Deprived).253 Zermati et al. Brief Definitive Report
the last steps of the differentiation and prepare the process
of enucleation. How active caspases selectively cleave some
target proteins such as acinus and lamin B without cleaving
other targets such as GATA-1 or DFF45/ICAD remains
currently unexplained. Caspases are only transiently acti-
vated during erythroid differentiation process, suggesting
that regulatory mechanisms prevent further amplification of
the proteolytic process that would lead to the cell demise.
Upon Epo deprivation or Fas activation, the transient
caspase activity is amplified via either the mitochondrial/
caspase-9 or the caspase-8 pathway, respectively, and lead
to apoptosis.
Therefore, in this report we have described a new func-
tion for caspases as enzymes critical for erythroid differenti-
ation. Further exploration of the role of caspases in ery-
throid cells and other hematopoietic lineages would be of
major interest for understanding the fate (differentiation
versus apoptosis) of hematopoietic cells upon different
physiological or pathological conditions.
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